These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 23190886)
1. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548 [TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630 [TBL] [Abstract][Full Text] [Related]
4. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934 [TBL] [Abstract][Full Text] [Related]
6. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. Tran NL; McDonough WS; Savitch BA; Sawyer TF; Winkles JA; Berens ME J Biol Chem; 2005 Feb; 280(5):3483-92. PubMed ID: 15611130 [TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Haile WB; Echeverry R; Wu F; Guzman J; An J; Wu J; Yepes M Neuroscience; 2010 Dec; 171(4):1256-64. PubMed ID: 20955770 [TBL] [Abstract][Full Text] [Related]
8. Development of an Fn14 agonistic antibody as an anti-tumor agent. Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB MAbs; 2011; 3(4):362-75. PubMed ID: 21697654 [TBL] [Abstract][Full Text] [Related]
9. TWEAK activation of the non-canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion. Armstrong CL; Galisteo R; Brown SA; Winkles JA Oncotarget; 2016 Dec; 7(49):81474-81492. PubMed ID: 27821799 [TBL] [Abstract][Full Text] [Related]
10. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571 [TBL] [Abstract][Full Text] [Related]
11. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity. Zaitseva O; Hoffmann A; Löst M; Anany MA; Zhang T; Kucka K; Wiegering A; Otto C; Wajant H Front Immunol; 2023; 14():1194610. PubMed ID: 37545514 [TBL] [Abstract][Full Text] [Related]
12. TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. Brown SA; Cheng E; Williams MS; Winkles JA PLoS One; 2013; 8(6):e65248. PubMed ID: 23750247 [TBL] [Abstract][Full Text] [Related]
13. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Willis AL; Tran NL; Chatigny JM; Charlton N; Vu H; Brown SA; Black MA; McDonough WS; Fortin SP; Niska JR; Winkles JA; Cunliffe HE Mol Cancer Res; 2008 May; 6(5):725-34. PubMed ID: 18505918 [TBL] [Abstract][Full Text] [Related]
14. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603 [TBL] [Abstract][Full Text] [Related]
15. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. Vince JE; Chau D; Callus B; Wong WW; Hawkins CJ; Schneider P; McKinlay M; Benetatos CA; Condon SM; Chunduru SK; Yeoh G; Brink R; Vaux DL; Silke J J Cell Biol; 2008 Jul; 182(1):171-84. PubMed ID: 18606850 [TBL] [Abstract][Full Text] [Related]
16. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. Polek TC; Talpaz M; Darnay BG; Spivak-Kroizman T J Biol Chem; 2003 Aug; 278(34):32317-23. PubMed ID: 12794080 [TBL] [Abstract][Full Text] [Related]
17. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Rosenblum MG; Cheung LH; Liu Y; Marks JW Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997 [TBL] [Abstract][Full Text] [Related]